Viking Therapeutics’ chief executive has told investors that almost all sites participating in the company’s Phase 3 clinical trial of VK-2735, its injectable obesity treatment, are now active, compared with earlier guidance of about half of sites being online. The faster-than-expected activation suggests the study is progressing on schedule, limiting the risk of higher costs or delays. Commentary from investors following the remarks also emphasized that Viking’s current cash position is expected to finance operations well beyond the completion of the Phase 3 program, reducing near-term funding risk. The operational update has revived market speculation that large drugmakers, including Pfizer, could pursue a takeover of Viking. One investor note circulated after the CEO’s comments suggested an offer north of $145 a share would be ‘ideal,’ though neither company has commented publicly on the possibility.